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Abstract
The interstitial lung diseases are a diverse collection of 
disorders characterized by impaired gas exchange, restricted 
physiology on lung function testing, and diffuse parenchymal 
lung infiltrates on radiography.  Although the interstitial lung 
diseases are many (Table 1), in routine clinical practice, the 
most commonly encountered in general internal medicine 
practice are sarcoidosis, idiopathic pulmonary fibrosis, and 
connective tissue disease-associated interstitial lung diseases. 
In immunocompromised patients, infection is the most common 
cause of diffuse lung infiltrates and must be ruled out before any 
attempt to treat with immune altering agents like corticosteroids. 
This review will focus on the more clinically significant recent 
advances in the broad field of interstitial lung disease research, 
with emphasis on the more common interstitial lung diseases 
occurring in immunocompetent hosts.  
Advances in the classification 
of idiopathic interstitial lung diseases
 Idiopathic pulmonary fibrosis (cryptogenic fibrosing 
alveolitis in the British literature), is one of the commonly 
encountered interstitial lung diseases, with an estimated 
prevalence of 5-20 per 100,000.1  Formerly, the term idiopathic 
pulmonary fibrosis was used to describe a variety of idiopathic 
interstitial pneumonias (listed in Table 1), characterized 
clinically by finger clubbing and bibasilar “velcro” crepitations 
on examination.  It is now apparent that these findings are 
not specific, and may be associated with any of the idiopathic 
interstitial pneumonias listed in Table 1.
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A recent joint statement by the American Thoracic Society 
and the European Respiratory Society, recommended that the 
term idiopathic pulmonary fibrosis be restricted to patients 
with the histopathologic lesion of usual interstitial pneumonia 
(Table 1).1  These guidelines resulted from the demonstration by 
numerous groups that the prognosis of patients with the lesion of 
usual interstitial pneumonia is distinctly worse than other types 
of idiopathic interstitial pneumonia.2-5  The median survival 
of patients with usual interstitial pneumonia is 3-5 years, 
and response to corticosteroid therapy is uniformly poor.1,2, 5 
In contrast, the other idiopathic interstitial pneumonias are 
frequently steroid-responsive, and most patients survive >10 
years after diagnosis.1,2  As a result of these recent findings, it 
is recommended that definite diagnosis with lung biopsy be 
considered in all patients suspected of having an idiopathic 
interstitial pneumonia. 
Advances in Diagnostic Imaging: 
the High Resolution CT scan 
The chest high resolution CT scan (HRCT) emerged over the 
1990s as an indispensable non-invasive diagnostic tool.6   Whereas 
conventional CT of the chest examines 7- to 10-mm slices 
obtained at 10-mm intervals, HRCT examines 1.0- to 1.5-mm 
slices at 10-mm intervals, illustrating lung parenchyma in much 
better detail than conventional CT.  In patients with interstitial 
lung disease, a systematic analysis of HRCT patterns is very 
important, permitting a diagnostic accuracy ranging from 50 to 
90% (in selected series comparing HRCT with histopathology), 
depending on disease entity, and the experience of the 
interpreting radiologist.7-11  Characteristic HRCT appearances 
have been described in sarcoidosis, idiopathic pulmonary 
fibrosis, pulmonary Langerhans’ cell Histiocytosis, pulmonary 
alveolar proteinosis, and lymphangioleiomyomatosis.10,12,13  In 
the appropriate clinical setting, a characteristic HRCT may 
enable a provisional diagnosis without resort to lung biopsy. 
HRCT is also useful to guide the selection of lung regions to 
biopsy when either bronchoscopic or surgical lung biopsy is 
planned.  It is important to remember that the utility of HRCT 
in diagnosing interstitial lung disease is directly proportional 
to the degree of expertise of attending radiologists reading 
the scans.  It is also essential to emphasize that confirmation 
of the diagnosis by histopathology remains essential prior to 
embarking on potentially toxic immunosuppressive trials, with 
the exception of those cases when the HRCT findings and clinical 
data are absolutely characteristic of the disease entity.  
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Lung biopsy: when, why, who, 
and how to biopsy
Changes in the classification of idiopathic interstitial 
pneumonias and novel therapies for interstitial lung diseases 
provide important reasons to pursue lung biopsy.  The decision 
to perform lung biopsy in patients with interstitial lung disease 
depends on available resources, and the potential benefit that 
knowledge of a specific histopathological diagnosis may have on 
therapy, or prognosis.  A practical example is the clinical situation 
of suspected idiopathic pulmonary fibrosis in a relatively young 
individual.  The fact that usual interstitial pneumonia has 
a remarkably worse prognosis than other histopathological 
subsets provides a compelling reason to recommend lung biopsy. 
However, in an elderly patient with identical clinical features, 
lung biopsy may not be in the patient’s best interest, since 
the risk of the procedure may outweigh the potential benefit 
of establishing a specific diagnosis.  Furthermore, long-term 
immunosuppressive therapy or lung transplantation may not 
be practical therapeutic options in older individuals.  
Lung biopsy may be performed by bronchoscopy or surgically 
(video-assisted surgical thoracotomy (VATS) or standard open 
thoracotomy).  Bronchoscopic lung biopsy has a limited role 
in the diagnosis of most interstitial lung diseases (with some 
exceptions), because tissue samples obtained are often too 
small to allow a specific histopathological diagnosis.  However, 
in patients suspected of having sarcoidosis, lymphangitic 
carcinomatosis, or eosinophilic pneumonia, bronchoscopic 
biopsy may be of substantial yield, and obviate the need for 
more invasive testing.  In medical centers with limited access to 
surgical lung biopsy, it is reasonable to consider bronchoscopic 
biopsy in all patients with equivocal HRCT patterns, particularly 
if one is contemplating a trial of immunosuppression.  
In addition to enabling lung biopsy, bronchoscopy also 
provides an opportunity to perform bronchoalveolar lavage 
(BAL).  BAL is safe, minimally invasive, and provides specific 
information in specific disorders.  Specific diagnoses that may 
be established by BAL include alveolar proteinosis, lymphangitic 
carcinomatosis, and alveolar cell carcinoma (which may 
mimic interstitial lung disease).  BAL also provides clinically 
helpful information in the following situations: (1) increased 
numbers of eosinophils in acute or chronic eosinophilic 
pneumonia, (2) asbestos bodies in asbestosis, (3) foamy cells 
with lamellar inclusions in amiodarone-induced pneumonitis, 
(4) hyperplastic and atypical type II pneumocytes in cytotoxic 
drug-induced lung injury, (5) an increase in CD1a positive cells 
in Langerhans’ cells histiocytosis, and (6) a bloody effluent with 
abundant hemosiderin in alveolar macrophages (>20% of total 
macrophage numbers) in diffuse alveolar hemorrhage secondary 
to pulmonary hemorrhage syndromes.  Although these findings 
are non-diagnostic (for example foamy cells may be seen in 
patients on amiodarone therapy without pneumonitis), they 
may provide useful additional clues to the potential cause of 
interstitial lung disease.  Quantifying the type of inflammatory 
cell infiltrate in BAL may also suggest specific diagnoses.  For 
instance, sarcoidosis and hypersensitivity pneumonitis are 
associated with a lymphocytosis, whereas chronic eosinophilic 
pneumonia is associated with an increased BAL eosinophil 
count.  
BAL has been used as a research tool to enhance 
understanding of pathogenesis of various types of interstitial 
lung disorders.  In this regard, BAL findings contributed to the 
characterization of idiopathic pulmonary fibrosis as a condition 
with a predominant T-helper-2 cytokine profile (Th-2: T-helper 
cells are subsets of T cells that express the CD4 receptor and 
Interstitial Lung Diseases  Examples
Granulomatous interstitial  Sarcoidosis
lung diseases Berylliosis
Interstitial lung diseases  Inhalation of foreign antigen (hypersensitivity pneumonitis)
of known cause Drug-induced (bleomycin,amiodarone,radiation,nitrofurantion,methotrexate)
 Connective tissue diseases (rheumatoid disease, scleroderma, 
     poly/dermatomyositis, SLE)
 Asbestos
Idiopathic interstitial pneumonias Usual interstitial pneumonia†
 Desquamative interstitial pneumonia
 Respiratory-bronchiolitis associated interstitial lung disease
 Bronchiolitis obliterans with organizing pneumonia
 Non specific interstitial pneumonia
 Acute  interstitial pneumonia
 Other forms of interstitial  Pulmonary Langerhans’ cell histiocytosis
lung disease Lymphangioleiomyomatosis
 Pulmonary Alveolar Proteinosis
 Lymphoid interstitial pneumonia
Table : Classification of the interstitial lung diseases*
*This is not a comprehensive list of the interstitial lung diseases, but a simplified classification system.
†Usual interstitial pneumonia is the histologic  lesion associated with the clinical diagnosis of idiopathic pulmonary fibrosis.
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play an important role in host responses to antigens), whereas 
BAL findings in sarcoidosis and hypersensitivity pneumonitis 
are characterized by a Th1-dominant profile.  The clinical value 
of BAL to assess the activity of disease processes and to provide 
prognostic information is still under debate.  
In a significant proportion of patients with interstitial lung 
disease, definitive diagnosis cannot be established without 
surgical lung biopsy.  In these situations, the risks of the 
surgical procedure have to be put into the context of presumed 
benefit of obtaining a specific diagnosis.  Surgical lung biopsy 
is associated with a relatively small but appreciable mortality 
(approximately 3%) even when performed by experienced 
surgical teams.  Adequate lung tissue samples should be at least 
2 cm in diameter and are ideally obtained from separate sites 
to increase diagnostic yield.  
Advances in the diagnostic approach 
for interstitial lung disease
Histopathologic evaluation was considered by many as the 
“gold standard” for diagnosis in interstitial lung disease.  That 
perception is now changing.  Although surgical lung biopsy 
often provides a definitive diagnosis in patients with challenging 
clinical lung disease, it is also fraught with certain difficulties 
that must be appreciated.  Recently, Flaherty and colleagues 
documented the problem of “sampling error”, in which divergent 
histopathologic diagnoses in two or more biopsy sites may be 
found.14  This is an extremely important issue since sampling 
lung tissue that is not significantly involved with the disease 
process may lead to an incorrect or improper characterization 
of the underlying lung disease.  The likelihood of sampling 
error should be minimized by using HRCT to select multiple 
biopsy sites representative of the full range of morphologic 
appearances.  A second important consideration is interobserver 
variation between pathologists.  In recent studies, substantial 
observer variation occurred between experienced specialist 
thoracic histopathologists.15  This may occur because of lack 
of familiarity with interstitial lung disease pathology, or due 
to histopathologic appearances that may be intermediate 
between two entities.  It is because of these issues that clinical 
and imaging data become key determinants of a final consensus 
diagnosis.  
With the advent of an ever-increasing range of serological, 
radiographic, and molecular diagnostic techniques, the diagnosis 
of many interstitial lung diseases has evolved significantly over 
the past decade.  The availability of new agents to treat specific 
interstitial lung diseases mandates that an accurate diagnosis 
be established prior to embarking on therapy that may be 
associated with considerable cost and adverse effects.  Numerous 
novel therapies are being tested in phase 2 and 3 clinical trials for 
various interstitial lung diseases, a testimony to the substantial 
recent advances made in molecular, genetic, and immunological 
understanding of interstitial lung diseases.  In the remainder 
of this review, advances in therapy of interstitial lung diseases 
will be discussed.
The idiopathic interstitial pneumonias and 
smoking-related interstitial lung diseases
There are no therapies known to improve survival of 
patients with idiopathic pulmonary fibrosis.  Traditionally, 
corticosteroids have been the mainstay of pharmacologic 
therapy, although this has never been proven in prospective or 
randomized trials to confer any objective improvement in lung 
function or survival advantage.  While some studies showed 
subjective benefit with corticosteroid use,16 others reported 
that corticosteroids and immunosuppressive treatments were 
ineffective.17-19  This discrepancy can be explained by the fact 
that some of the earlier studies were contaminated by the 
inclusion of corticosteroid-sensitive idiopathic interstitial lung 
diseases such as non-specific interstitial pneumonia.  The lack of 
effectiveness of prednisone and other anti-inflammatory agents 
brought about a important change in what is currently believed 
to be relevant to the pathophysiology of idiopathic pulmonary 
fibrosis.  Previously considered to be an inflammatory disease, 
expert opinion and general consensus have now shifted to a 
concept of abnormal tissue healing resulting in fibrosis as a 
consequence of a predominance of T helper lymphocyte type 2 
cytokines (or alternatively a relative lack of opposing T helper 
type 1 cytokines).20  
The frustration resulting from lack of effective therapies 
together with emerging concepts on pathophysiology that 
challenge the inflammatory hypothesis have fueled an enormous 
amount of activity, culminating in numerous ongoing clinical 
trials.  Based on molecular studies and laboratory animal 
studies, numerous agents have been proposed for management 
of idiopathic pulmonary fibrosis, and a number of these agents 
are currently undergoing testing in randomized clinical trials.  
Interferon-gamma is one of the novel biological 
agents.  A preliminary study conducted on 18 patients with 
histopathologically-proven idiopathic pulmonary fibrosis treated 
for 12 months with interferon gamma-1b plus prednisolone was 
associated with substantial improvement in lung function.21 
Unfortunately, this study was not confirmed by a large phase 
3 multi-center placebo-controlled double-blinded randomized 
trial, that failed to show a beneficial effect of interferon-
gamma therapy on overall mortality and progression in lung 
function decline.22  Subset analysis from this trial suggested 
that treatment with interferon-gamma may confer a survival 
benefit to patients with mild to moderate disease (as defined 
by the degree of restriction on pulmonary function testing). 
This conclusion is of doubtful significance considering that it 
is based on post-hoc sub-group analysis and therefore may not 
be statistically valid.  There are also concerns regarding the 
use of interferon-gamma in patients with advanced disease, as 
there is data to suggest that patients with advanced idiopathic 
pulmonary fibrosis have a worse outcome with interferon-
gamma therapy.23  Before additional data from larger trials on 
interferon-gamma are forthcoming, it is reasonable to conclude 
that there is no convincing evidence to support the routine use 
of interferon gamma, with the exception of patients with early 
idiopathic pulmonary fibrosis (defined by FVC>55% predicted 
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and symptom onset of less than 12 months).  Considering the 
considerable cost associated with this therapy (> $50,000.00 
annually per patient in the US) and potential adverse effects, 
significant caution should be exercised prior to prescribing this 
medication, even to patients with early stage disease. 
Other novel agents being evaluated include inhibitors of 
the pro-inflammatory cytokine tumor necrosis factor-alpha 
(TNF-alpha), inhibitors of endothelin-1 (bosentan), and imatinib 
mesylate (a protein-tyrosine kinase inhibitor).  Enthusiasm for 
these therapies in idiopathic pulmonary fibrosis is based on in 
vitro data, animal studies, and reports of efficacy in isolated 
patients or small case series.24-26  Data from ongoing clinical trials 
should be available in the next 1 to 3 years.  The anti-oxidant 
N-acetylcysteine (NAC) is also under investigation in a phase 3 
clinical trial that should be completed in the near future.  Other 
molecular targets under investigation include antagonists of 
transforming growth factor-beta (TGF-b, a cytokine with a 
prominent role in the formation of scar tissue) and biological 
inhibitors of integrin receptors (integrins are a superfamily of 
cell surface proteins that regulate binding of cells to extracellular 
matrix components). 
Although ineffective in the management of idiopathic 
pulmonary fibrosis, corticosteroids are very useful in the 
management of other interstitial lung diseases including BOOP, 
non-specific interstitial pneumonia, desquamative interstitial 
pneumonia and others.  It is important to remember that 
many of the aforementioned diseases may be clinically and 
radiographically very similar to idiopathic pulmonary fibrosis, 
and that one should strive to make an accurate diagnosis prior 
to dismissing the use of corticosteroids on the presumption of 
probable pulmonary fibrosis. 
Another recent concept that has modified the way we think 
about idiopathic interstitial pneumonias is the appreciation that 
smoking may induce or alter the course of certain interstitial lung 
diseases.  It is apparent that some interstitial lung diseases occur 
almost exclusively in smokers, and are sometimes collectively 
referred to as smoking-related interstitial lung diseases.27, 28 
These disorders include desquamative interstitial pneumonia, 
respiratory bronchiolitis-associated interstitial lung disease, 
and pulmonary Langerhans’ cell histiocytosis.28  In addition to 
the causal relationship to smoking, these diseases have been 
reported to spontaneously improve upon smoking cessation,29 
can recur in a transplanted lung following the resumption of 
smoking, and histopathological findings of all of these lesions 
may occur in the same individual.30  The recognition that these 
diseases are related to smoking is not just a matter of semantics. 
The cornerstone of therapy for these patients is smoking 
cessation, in the absence of which, immunosuppressive therapy 
may have no effect whatsoever.  In addition, smoking is now 
considered to be a risk factor for the development of idiopathic 
pulmonary fibrosis and acute eosinophilic pneumonia.31
Sarcoidosis
The cornerstone of pharmacotherapy for sarcoidosis remains 
corticosteroids; however, not all patients with sarcoidosis need 
therapy.  A recently consensus statement published by American 
Thoracic and European Respiratory Societies provides an 
excellent review on the challenges associated with treatment 
of sarcoidosis, and confirms prior opinion that cardiac or 
neurological involvement, hypercalcemia, and ocular disease 
which cannot be controlled by topical therapy are best managed 
by judicious use of oral corticosteroid therapy.32  Management of 
pulmonary sarcoidosis (which occurs in about 90% of patients) 
remains challenging.  It is well-established that patients with 
stage 1 disease (bilateral hilar adenopathy but no lung infiltrates 
on chest radiograph) do not require therapy and generally 
have an excellent prognosis.  Patients with stage 2 or 3 disease 
(involvement of lung parenchyma in association with or without 
hilar adenopathy) are the ones at risk of developing progressive 
lung fibrosis and irreversible lung injury.  Although intuitively 
patients with stage 2 or 3 disease would seem to be the sub-group 
to whom aggressive therapy should be targeted, controversy and 
doubt remain regarding the timing of use of oral corticosteroid 
therapy, the dose and duration of therapy, and ultimately the 
long-term effect of corticosteroid therapy on lung function.  A 
systematic review of published studies on corticosteroid therapy 
in stage 2 and 3 pulmonary sarcoidosis concluded that use of oral 
steroids was associated with improvement in chest radiography 
and small improvements in vital capacity and diffusing capacity 
measurements.33  A more recent systematic analysis of published 
data reported that oral steroids improved radiographic findings, 
symptoms and spirometry of patients with Stage 2 and 3 
disease over a period of 3-24 months.  However, there was little 
evidence that objective lung function improved.34  Although 
the optimal dose and duration of corticosteroids has not been 
studied in randomized trials, it is currently recommended 
that for patients requiring treatment, an initial dosage of 
20-40 mg/day of prednisone or its equivalent on alternate 
days is used with evaluation of response following 3 months. 
Among steroid responders, the dose should be slowly tapered 
to 5-10 mg/day or an every other day regimen, and treatment 
continued for a minimum of 12 months.  Azathioprine is useful 
as a steroid sparing agent in patients requiring long-term oral 
corticosteroids.  
For patients with progressive symptoms in spite of 
adequate steroid therapy, numerous second-line agents 
have been proposed as effective for disease control, yet 
none have undergone rigorous testing by randomized trials. 
Hydroxychloroquine is effective for control of cutaneous 
sarcoid,35, 36 and has also been successfully used to treat 
sarcoid-associated hypercalcemia, arthritis, neurological 
disease, and pulmonary disease.37-39  The TNF-alpha inhibitors 
infliximab and etanercept have both been used in small case 
series of patients with sarcoidosis refractory to corticosteroid 
therapy, with conflicting outcomes.40-46  Most reports suggest 
that Infliximab is superior to Etanercept in controlling severe 
sarcoidosis and should be the agent of choice if TNF-alpha 
inhibition is to be considered in patients with severe, refractory 
sarcoid.  Other agents that might function as antagonists of 
TNF-alpha include Pentoxifylline  and  Thalidomide. 
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Pentoxifylline has been reported to have efficacy in the 
management of various complications associated with 
sarcoidosis, and is a useful alternative to high-dose 
corticosteroids or monoclonal TNF-alpha inhibitors in selected 
patients.47  Thalidomide is predominantly used to manage 
cutaneous sarcoid and has very little proven activity for other 
manifestations of sarcoid.36  Recently, oral Methotrexate (10-
25mg/week) was reported to have some efficacy in controlling 
the interstitial lung disease associated with sarcoid, although 
it is unclear whether it has any efficacy as a single-agent or as a 
steroid-sparing agent.48  Use of methotrexate in any patient with 
interstitial lung disease is also complicated by the potential for 
development of methotrexate-associated pneumonitis, which 
may be impossible to distinguish from natural progression of 
the underlying lung disease.49  
Interstitial lung disease associated with 
connective tissue diseases
Interstitial lung disease frequently complicates the course 
of many rheumatic diseases and can result from a variety 
of histological lesions identical to the idiopathic interstitial 
pneumonias.50  Although the relative frequency of occurrence 
of these histopathological lesions is not definitively established, 
it seems that non-specific interstitial pneumonia accounts for 
a large proportion of rheumatic-associated interstitial lung 
disease.  Whether the natural history and response to therapy 
of interstitial lung disease associated with rheumatic disease 
is identical to that of the same lesions occurring in patients 
with no underlying disease is uncertain, and needs to be 
addressed in prospective studies.  In parallel to what is observed 
with idiopathic pulmonary fibrosis, the occurrence of usual 
interstitial pneumonia in patients with connective tissue disease 
generally portends a poor response to corticosteroid therapy 
and an unfavorable prognosis.  It is still unclear whether usual 
interstitial pneumonia occurring in patients with connective 
tissue disease is the same disease as that occurring in the 
sporadic idiopathic form, and recent studies suggest that subtle 
but important differences exist.51  Other forms of interstitial 
pneumonia, particularly non-specific interstitial pneumonia, 
are often steroid responsive and have a more favorable long-
term prognosis.  
Treatment of rheumatoid disease-associated interstitial 
lung disease depends on the histopathology, extent of other 
organ involvement, and the potential presence of secondary 
pulmonary hypertension.  Many patients are treated with 
corticosteroids at doses of 0.5-1mg/kg/day, either as a single 
agent or in combination with azathioprine or cyclophosphamide. 
Although commonly used in practice, these immunosuppressive 
programs have never been subjected to rigorous prospective 
trials, and the risk to benefit ratio remains a subject of 
speculation.  Recent studies suggest that cyclophosphamide 
and prednisone combination therapy seems to stabilize 
scleroderma-associated interstitial lung disease in the 
majority of patients.52  However, most of these patients have 
the non-specific interstitial pneumonia lesion that is typically 
very responsive to corticosteroid therapy, and the role of 
cyclophosphamide as an adjuvant remains contentions.  Other 
treatments currently under investigation for the management 
of rheumatic disease-associated interstitial lung diseases are 
infliximab and bosentan.  
Pulmonary Alveolar Proteinosis
Pulmonary alveolar proteinosis is a rare interstitial lung 
disease characterized by the accumulation of proteinecaous 
exudates in the alveolar spaces.  Although rare, this disease is 
worth mentioning because specific treatment is now available 
for this condition.  Granulocyte colony macrophage stimulating 
factor (GM-CSF: a cytokine that stimulates the granulocytes, 
macrophages, dendritic cells, and bone-marrow precursors 
of platelets) administered by either subcutaneous injection or 
aerosolized form, has recently been demonstrated to effectively 
control disease course and provides a very useful alternative to 
the traditional therapy of whole lung lavage.53, 54  
Management of Pulmonary Hypertension 
Complicating Interstitial Lung Diseases
It is increasingly evident that many patients with interstitial 
lung disease develop clinically significant pulmonary 
hypertension.  Pulmonary hypertension may occur as a result 
of chronic hypoxemic vasoconstriction, direct pulmonary 
vascular involvement by the disease process, and obliteration 
of pulmonary vasculature as a result of destruction of normal 
lung tissue.  Pulmonary hypertension affects right ventricular 
function by imposing afterload on the right ventricle, leading 
to reduced right-sided cardiac function, cor pulmonale, and 
reduced cardiac output.  The development of pulmonary 
hypertension in patients with interstitial lung disease does 
not occur solely in advanced stages of disease and may even 
be present at the time of presentation.  Until recently, many 
clinicians hesitated to treat secondary pulmonary hypertension 
because of limited availability of oral or intravenous drugs that 
affect the pulmonary circulation without causing excessive 
systemic vasodilatation.  The situation has changed with the 
availability of novel oral agents like the prostacyclin analogue 
beraprost sodium, the phosphodiesterase inhibitor sildenafil, 
and the endothelin-1 antagonist bosentan.  These agents 
already have an established role in the management of primary 
pulmonary hypertension, but require careful study for a role 
in the setting of interstitial lung disease.  These medications 
(and others currently in phase 1-2 studies) may have beneficial 
effects that extend beyond vasodilation, including anti-fibrotic 
and anti-inflammatory effects.55-57  Whether or not reducing 
the pulmonary artery pressure of patients with secondary 
pulmonary hypertension complicating interstitial lung disease 
alters mortality is unknown.  
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Final comments
The interstitial lung diseases are a fascinating collection of 
lung diseases that occur at any age group and may develop as a 
consequence of an extraordinarily broad collection of systemic 
diseases.  The importance of a careful history and physical 
examination cannot be overstated, and may obviate many 
expensive diagnostic tests.  The diagnosis and management of 
interstitial lung diseases often requires active discussion and 
collaboration between the clinician, surgeon, pathologist and 
radiologist.  Recent studies challenge the dogma that lung biopsy 
is the “gold-standard” for diagnosing interstitial lung disease. 
Rather than the lung biopsy per se, the new gold-standard for 
the diagnosis is the combined input from the diagnostic studies 
(radiology, pathology, and functional testing) and the clinical 
evaluation that allows a confident diagnosis in many situations. 
It is necessary that the clinician review all pertinent radiological 
and histopathological data if the clinical picture does not fit with 
the findings on diagnostic testing.  
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